<?xml version="1.0" encoding="UTF-8"?>
<p>The primary endpoints – retention in HIV care and viral suppression six months or more after ART initiation among those retained – were chosen because they are proxy indicators for long‐term HIV‐related health outcomes, mortality and transmission [
 <xref rid="jia225610-bib-0012" ref-type="ref">12</xref>, 
 <xref rid="jia225610-bib-0013" ref-type="ref">13</xref>]. We also present the effect of EAAA on a combined endpoint of retention and viral suppression. The results for several secondary endpoints (ART initiation, drug resistance, HIV diseases progression, cost per patient per year) for this trial are in preparation or under review at this time. The results for patient satisfaction, adherence and mortality have been published elsewhere [
 <xref rid="jia225610-bib-0014" ref-type="ref">14</xref>, 
 <xref rid="jia225610-bib-0015" ref-type="ref">15</xref>, 
 <xref rid="jia225610-bib-0016" ref-type="ref">16</xref>].
</p>
